DC-15442
/ DeepCure
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 10, 2025
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models
(PRNewswire)
- "In preclinical evaluations, DC-15442 achieved nearly 100% inhibition of pSTAT6 in the acute ovalbumin (OVA) allergy models, which outperforms IL-4Ra antibodies and other STAT6 inhibitors. In direct comparisons using the MC903 atopic dermatitis model, DC-15442 matched dupilumab's effectiveness, significantly reducing serum IgE levels to those seen in healthy controls. Additionally, DC-15442 has a dramatic effect on lung function in asthma models, restoring lung function to almost the same levels as healthy controls, with an effect superior to a leading JAK inhibitor (upadacitinib) and dexamethasone."
Preclinical • Allergy • Asthma • Atopic Dermatitis
1 to 1
Of
1
Go to page
1